

Bone Health

www.cdri.res.in



CSIR-Central Drug Research Institute
Lucknow, India

Global data

Over 200 million women suffer from Osteoporosis
Over 8.9 million fractures annually because of Osteoporosis
Over 100 million people suffer from Osteoarthritis

CSIR-CDRI Products in Market



Reunion

Standardized extract of *Dalbergia sissoo*

Indication: Rapid fracture healing and mitigating bone loss in post-menopausal women

IP Status: US20140079834A1 & others

Market Status: Available in Indian market as Ayurvedic medicine

Product will be launched in US market soon

Joint Fresh

Formulation of *Spinacia oleracea*

Indication: Cartilage and joint health

IP Status: Patent filed

Market Status: Available in Indian market as Nutraceutical

Product is planned for marketing in US market



Products in Pipeline

Candidate Drug 99/373 for post-menopausal osteoporosis

IP Status: US7582653B2 & others

Current status: DCGI Permission Received for Phase I Clinical Trial

An orally active small molecule S-007-1500 for rapid fracture healing

IP Status: US8686028B2 & others

Current status: IND enabling studies – Toxicity studies in primate model

Phytopharmaceutical lead: a plant-derived formulation for glucocorticoid-induced osteoporosis

IP Status: Patent being filed

Current Status: Pre-clinical studies

A controlled-release micro-capsule formulation of kaempferol for enhanced osteogenic action

IP Status: US8496964B2 & others

Status: PoC studies completed